Core Viewpoint - Ascentage Pharma presented promising results from a Phase II study of Lisaftoclax, a Bcl-2 selective inhibitor, for treating relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) at the ASH Annual Meeting, supporting its recent NDA approval in China [1][6][7] Company Overview - Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [16] - The company has a pipeline that includes inhibitors targeting key apoptotic pathway proteins and next-generation kinase inhibitors [16] Study Results - Lisaftoclax monotherapy showed a 62.5% objective response rate (ORR) in heavily pretreated BTK-refractory R/R CLL/SLL patients, with a median progression-free survival of 23.89 months [6][11] - Among 77 enrolled patients, 42.9% had chromosomal complex karyotype, 39% had del(17p)/TP53 mutation, and 53.2% had unmutated IGHV, indicating a high-risk patient population [3][13] - The study reported no tumor lysis syndrome (TLS) and a manageable safety profile, with frequent grade ≥3 treatment-related adverse events being hematologic toxicities [14][6] Clinical Significance - The results highlight Lisaftoclax's potential as a new treatment option for patients with high-risk CLL/SLL, addressing an urgent clinical need for effective therapies [5][7] - The study's findings suggest that even in ultra-high-risk patients, Lisaftoclax can achieve deep and durable responses, with 21.8% of patients achieving minimal residual disease (MRD) negativity in peripheral blood [11][15] Future Directions - Ascentage Pharma is conducting four global registrational Phase III studies for Lisaftoclax in various indications, including CLL/SLL, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) [4][18] - The company aims to accelerate clinical programs to provide safe and effective therapies to patients globally [7]

Core Viewpoint - The Hong Kong stock market is experiencing fluctuations, but the innovative pharmaceutical sector is showing resilience with notable gains in specific stocks and ETFs [1] Group 1: Market Performance - The Hong Kong innovative pharmaceutical sector saw stocks like Ascentage Pharma-B, Kelun-Biotech, and Hengrui Medicine rise slightly despite market adjustments [1] - The Hong Kong Innovative Drug ETF (159567) opened higher, initially rising by 0.71% before retreating with the market [1] Group 2: Fund Flows and Growth - Since October, the Hong Kong Innovative Drug ETF (159567) has seen an increase of 1.928 billion shares, with a cumulative net inflow of over 1.6 billion yuan, surpassing 10 billion shares for the first time [1] - Analysts indicate that China is becoming a significant player in global innovative drug development, with increasing overseas licensing transactions driving sector growth [1] Group 3: Future Outlook - The pharmaceutical industry is entering a critical phase characterized by "innovation realization + global layout," supported by population and domestic demand, as well as comprehensive manufacturing capabilities [1] - By 2026, there are opportunities to focus on innovative commercialization, global breakthroughs, policy optimization, and industry mergers and acquisitions [1] Group 4: Investment Opportunities - The Hong Kong Innovative Drug ETF tracks the CSI Hong Kong Stock Connect Innovative Drug Index, reflecting the performance of listed companies in the innovative drug sector [1] - Investors can access the Hong Kong Innovative Drug ETF through linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward potential of the sector [1]

Core Viewpoint - Ascentage Pharma-B (06855) saw a stock increase of over 6%, currently trading at 64.2 HKD with a transaction volume of 19.93 million HKD, following the announcement of the global registration Phase III clinical trial POLARIS-1 for its novel drug Olverembatinib (brand name: Nilotinib) in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients, which has received approval from both the FDA and EMA [1][2] Group 1 - The POLARIS-1 study is the second global registration Phase III trial for Nilotinib approved by regulatory agencies in Europe and the U.S. [1] - The trial will enroll patients across multiple countries and centers, accelerating the market entry of Nilotinib, particularly in Europe and the U.S. [1] - The latest data from the POLARIS-1 study will be presented at the upcoming 2025 American Society of Hematology (ASH) annual meeting, marking the first public disclosure of this data [2] Group 2 - Preliminary results indicate that the molecular minimal residual disease (MRD) negative rate and complete response (CR) rate for patients treated with Nilotinib and low-intensity chemotherapy are around 65%, significantly higher than similar products under the same conditions [2] - The treatment has shown effective results even in high-risk subtypes, such as those with IKZF1plus gene mutations [2] - The safety profile of the combination therapy is favorable, with a low and manageable incidence of side effects [2]

Core Viewpoint - Ascentage Pharma-B (06855) saw a stock increase of over 6%, currently trading at 64.2 HKD with a transaction volume of 19.93 million HKD, following the announcement of the global registration Phase III clinical trial POLARIS-1 for its novel drug Olverembatin (brand name: Nairik) in treating newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients, which received approval from both the FDA and EMA [1][2]. Group 1 - The POLARIS-1 study is the second global registration Phase III trial for Nairik approved by regulatory agencies in Europe and the US, which will expedite its market entry, particularly in Europe and the US [1]. - The POLARIS-1 study's latest progress will be presented at the upcoming 2025 American Society of Hematology (ASH) annual meeting, marking the first public disclosure of the study data [2]. - Preliminary data from the study indicates that the molecular MRD (minimal residual disease) negative rate and molecular MRD negative complete response (CR) rate for patients treated with Nairik combined with low-intensity chemotherapy reached approximately 65%, significantly outperforming similar products under comparable conditions [2]. Group 2 - The treatment regimen demonstrated excellent safety profiles, with a low and manageable incidence of side effects, even for high-risk subtypes such as those carrying the IKZF1plus gene mutation [2].

Core Viewpoint - Ascentage Pharma-B (06855) has seen a stock price increase of over 6%, currently trading at 64.2 HKD, following the announcement of the global Phase III clinical trial POLARIS-1 for its novel drug Olverembatinib (brand name: Nilotinib) in treating newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) patients, which has received approval from both the FDA and EMA [1][2] Group 1 - The POLARIS-1 study is the second global Phase III trial for Nilotinib approved by major regulatory agencies in Europe and the U.S., which will expedite its market entry, particularly in Europe and the U.S. [1] - The study will present its latest findings at the upcoming 2025 American Society of Hematology (ASH) annual meeting, marking the first public disclosure of the data [2] - Preliminary data indicates that the molecular MRD (minimal residual disease) negative rate and molecular MRD negative complete response rate for patients treated with Nilotinib combined with low-intensity chemotherapy are around 65%, significantly outperforming similar products under comparable conditions [2] Group 2 - The treatment has shown promising efficacy even in high-risk subtypes, such as those with IKZF1plus gene mutations, demonstrating good therapeutic outcomes [2] - The safety profile of the combination therapy is favorable, with a low and manageable incidence of adverse effects [2]

Core Viewpoint - The announcement highlights the approval of the global Phase III clinical trial (POLARIS-1) for the novel drug Orebatinib (brand name: Nairike®) in treating newly diagnosed Ph+ acute lymphoblastic leukemia (ALL) patients, which is expected to accelerate its market entry in Europe and the US [1][2]. Group 1: Clinical Trial Details - The POLARIS-1 study is an international, multicenter, randomized, open-label Phase III clinical trial aimed at evaluating the efficacy and safety of Nairike® in combination with chemotherapy for newly diagnosed Ph+ ALL patients [1]. - The trial has received clinical trial approval from China's CDE in 2023 and has been rapidly initiated [1]. Group 2: Study Results and Efficacy - Preliminary data from the POLARIS-1 study indicates that the molecular MRD (minimal residual disease) negative rate and molecular MRD negative complete response (CR) rate in patients treated with Nairike® and low-intensity chemotherapy are approximately 65%, significantly higher than similar products under the same conditions [2]. - The treatment shows promising efficacy even in high-risk subtypes, such as those with IKZF1plus gene mutations, and demonstrates excellent safety with low and manageable adverse effects [2]. Group 3: Market Position and Collaborations - Nairike® is a first-in-class oral third-generation TKI and the first third-generation BCR-ABL inhibitor approved in China, with commercialization in China managed by the company and Innovent Biologics [3]. - The drug has received multiple indications for treatment in CML resistance areas and is included in the national medical insurance drug list [3]. - The company has signed an exclusive option agreement with Takeda for the global development and commercialization rights of Nairike®, excluding certain regions in Greater China [3].

Core Viewpoint - The announcement highlights the approval of the global Phase III clinical trial (POLARIS-1) for the novel drug Orebatin (brand name: Nairike) in treating newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients, which is expected to accelerate its market entry in Europe and the US [1][2]. Group 1: Clinical Trial Details - POLARIS-1 is an international, multicenter, randomized, open-label Phase III clinical trial aimed at evaluating the efficacy and safety of Nairike in combination with chemotherapy for newly diagnosed Ph+ ALL patients [1]. - The trial has received clinical trial approval from China's CDE in 2023 and has been rapidly initiated [1]. Group 2: Efficacy and Safety Data - Preliminary data from the POLARIS-1 study indicates that the molecular minimal residual disease (MRD) negative rate and complete response (CR) rate for patients treated with Nairike and low-intensity chemotherapy are approximately 65%, significantly higher than similar products under comparable conditions [2]. - The safety profile of the combination treatment is favorable, with a low and manageable incidence of adverse effects [2]. Group 3: Market Context and Product Background - Ph+ ALL accounts for about 20%-30% of adult ALL cases, characterized by high relapse rates and poor prognosis, particularly in older patients [2]. - Nairike is a third-generation TKI and the first of its kind approved in China, with commercial promotion in China being jointly managed by the company and Innovent Biologics [3]. - The drug has received multiple indications for treatment in the CML resistant field and is included in the national medical insurance drug list [3].

Core Insights - The company Ayshun Pharmaceutical-B (06855) has received approval from the FDA and EMA to conduct the global Phase III clinical trial (POLARIS-1) for its novel drug Orebatinib (brand name: Nairike®) in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) patients [1][2] - The POLARIS-1 study is an international, multicenter, randomized, open-label Phase III trial aimed at evaluating the efficacy and safety of Nairike® combined with chemotherapy in Ph+ ALL patients [1] - Preliminary data from the POLARIS-1 study indicates a molecular minimal residual disease (MRD) negative rate and complete response (CR) rate of approximately 65% in newly diagnosed Ph+ ALL patients treated with Nairike® and low-intensity chemotherapy, showing significant improvement compared to similar products [2] Company Developments - Nairike® is a first-in-class oral third-generation TKI and the first third-generation BCR-ABL inhibitor approved in China, with commercialization in China managed by Ayshun Pharmaceutical and Innovent Biologics [3] - The drug has received multiple indications for treatment in CML resistance areas and is included in the national medical insurance drug list in China [3] - Ayshun Pharmaceutical signed an exclusive option agreement with Takeda regarding Orebatinib, granting Takeda global development and commercialization rights, excluding certain regions in Greater China [3]

Core Viewpoint - Ascentage Pharma has received regulatory clearance from the US FDA and EMA to conduct a global Phase III study of olverembatinib for treating newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), marking a significant advancement in its clinical development efforts [1][3]. Company Overview - Ascentage Pharma Group International is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer, with a strong pipeline that includes third-generation kinase inhibitors and Bcl-2 inhibitors [6][7]. Clinical Development - The POLARIS-1 trial is a global, multicenter, randomized controlled Phase III study aimed at evaluating the efficacy and safety of olverembatinib in combination with chemotherapy for newly diagnosed Ph+ ALL patients [2][3]. - The trial is designed to accelerate the registration process for olverembatinib, particularly in the US and European markets, with simultaneous patient enrollment across multiple countries [1][2]. Efficacy and Safety Data - Preliminary data from the POLARIS-1 study indicates that approximately 65% of treatment-naïve Ph+ ALL patients achieved minimal residual disease (MRD) negativity and molecular MRD-negative complete response (CR) after three treatment cycles, significantly outperforming other drugs in the same class [3]. - The combination therapy demonstrated a favorable safety profile, with a low incidence of manageable adverse events [3]. Market Context - Ph+ ALL accounts for 20%-30% of all adult acute lymphoblastic leukemia cases and is associated with high relapse rates and poor prognosis, particularly in elderly patients [3]. - Prior to the introduction of tyrosine kinase inhibitors (TKIs), the five-year overall survival rate for Ph+ ALL was less than 20%, highlighting the need for improved treatment options [3]. Strategic Partnerships - Ascentage Pharma has signed an exclusive option agreement with Takeda for olverembatinib, which could lead to Takeda licensing global rights for the drug outside of certain regions, enhancing its commercial potential [4].

Core Insights - Ascentage Pharma has received FDA and EMA clearance for a global Phase III study of olverembatinib in combination with chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients [1][2] - The POLARIS-1 trial aims to accelerate the registration process of olverembatinib in the US and European markets [1] - Initial data from the POLARIS-1 study indicates a 65% minimal residual disease (MRD) negativity rate and molecular MRD-negative complete response (CR) rate after three treatment cycles, showing improved efficacy compared to existing therapies [3] Company Overview - Ascentage Pharma is a global biopharmaceutical company focused on developing novel therapies for unmet medical needs in cancer [6] - The company has a diverse pipeline, including olverembatinib, a third-generation BCR-ABL inhibitor, and lisaftoclax, a Bcl-2 inhibitor [7][8] - Olverembatinib has been approved in China for multiple indications in drug-resistant chronic myeloid leukemia (CML) and is included in the National Reimbursement Drug List (NRDL) [7] Clinical Development - The POLARIS-1 study is a multicenter, randomized controlled trial designed to evaluate the safety and efficacy of olverembatinib in Ph+ ALL patients [2] - The study has also been initiated in China following clearance from the China Center for Drug Evaluation (CDE) [2] - Olverembatinib has received Breakthrough Therapy Designation from the China CDE, highlighting its potential in treating Ph+ ALL [3][4] Strategic Partnerships - Ascentage Pharma has signed an exclusive option agreement with Takeda for olverembatinib, which could lead to Takeda licensing global rights outside of certain regions [4] - The company collaborates with various leading biotechnology and pharmaceutical firms, enhancing its research and development capabilities [9]